LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

Search

Charles River Laboratories International Inc

Закрыт

СекторЗдравоохранение

179.28 -2.52

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

181.52

Макс.

185.77

Ключевые показатели

By Trading Economics

Доход

2.9M

56M

Продажи

-27M

1B

P/E

Средняя по отрасли

592.3

80.03

Прибыль на акцию

2.43

Рентабельность продаж

5.529

Сотрудники

18,700

EBITDA

-23M

198M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+10.28% upside

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-136M

8.7B

Предыдущая цена открытия

181.8

Предыдущая цена закрытия

179.28

Новостные настроения

By Acuity

15%

85%

20 / 374 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Strong Bullish Evidence

Charles River Laboratories International Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

3 дек. 2025 г., 23:21 UTC

Отчет
Приобретения, слияния, поглощения

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3 дек. 2025 г., 23:14 UTC

Приобретения, слияния, поглощения

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3 дек. 2025 г., 22:01 UTC

Главные движущие силы рынка

Costco Wholesale Reports Higher Monthly Sales

3 дек. 2025 г., 21:38 UTC

Отчет

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3 дек. 2025 г., 23:59 UTC

Обсуждения рынка

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3 дек. 2025 г., 23:49 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

3 дек. 2025 г., 23:49 UTC

Обсуждения рынка

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3 дек. 2025 г., 23:49 UTC

Обсуждения рынка

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3 дек. 2025 г., 23:13 UTC

Обсуждения рынка

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3 дек. 2025 г., 23:10 UTC

Отчет

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3 дек. 2025 г., 23:08 UTC

Обсуждения рынка

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3 дек. 2025 г., 23:06 UTC

Приобретения, слияния, поглощения

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3 дек. 2025 г., 22:59 UTC

Приобретения, слияния, поглощения

EQB to Buy PC Financial From Loblaw for About $573.5M

3 дек. 2025 г., 22:45 UTC

Обсуждения рынка

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3 дек. 2025 г., 22:20 UTC

Отчет

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3 дек. 2025 г., 22:19 UTC

Отчет

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3 дек. 2025 г., 22:17 UTC

Отчет

Salesforce Working to Add Voice to Agentforce, CEO Says

3 дек. 2025 г., 22:16 UTC

Отчет

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3 дек. 2025 г., 22:15 UTC

Отчет

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3 дек. 2025 г., 22:10 UTC

Приобретения, слияния, поглощения

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3 дек. 2025 г., 22:09 UTC

Приобретения, слияния, поглощения

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3 дек. 2025 г., 21:50 UTC

Обсуждения рынка

Auto & Transport Roundup: Market Talk

3 дек. 2025 г., 21:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

3 дек. 2025 г., 21:49 UTC

Отчет

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 дек. 2025 г., 21:23 UTC

Отчет

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3 дек. 2025 г., 21:19 UTC

Отчет

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 дек. 2025 г., 21:06 UTC

Отчет

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3 дек. 2025 г., 21:04 UTC

Отчет

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3 дек. 2025 г., 21:04 UTC

Отчет

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3 дек. 2025 г., 21:03 UTC

Отчет

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Сравнение c конкурентами

Изменение цены

Charles River Laboratories International Inc Прогноз

Целевая цена

By TipRanks

10.28% рост

Прогноз на 12 месяцев

Средняя 192.73 USD  10.28%

Максимум 225 USD

Минимум 165 USD

Основано на мнении 12 аналитиков Wall Street, спрогнозировавших целевые цены для Charles River Laboratories International Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

12 ratings

7

Покупка

5

Удержание

0

Продажа

Техническая оценка

By Trading Central

117.16 / 144.77Поддержка и Сопротивление

Краткосрочная

Strong Bullish Evidence

Среднесрочная

Weak Bullish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

20 / 374Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat